AlphaStocks

AZN vs INVA

ASTRAZENECA PLC vs Innoviva, Inc. — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

INVA

Innoviva, Inc.

7.9

Strong Buy

$23.42

AZN vs INVA: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while Innoviva, Inc. (INVA) scores 7.9/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, Innoviva, Inc. trades at 7.3x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNINVA
Scores & Fundamentals
Composite Score8.4/107.9/10
RatingStrong BuyStrong Buy
Price$200.99$23.42
P/E Ratio30.47.3
ROE21.9%24.8%
Market Cap$312B$2B
Fair Value$192.63
Dividend Yield1.6%
Sector Rank#3 of 1127#11 of 1127
Model Verdicts
PiotroskiStrongAttractive
BuffettStrongAttractive
GrahamCautionAttractive
LynchNeutralStrong
GreenblattNeutralStrong
View full AZNanalysis →View full INVAanalysis →
Compare any two stocks →

AZN vs INVA: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and Innoviva, Inc. (INVA) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to INVA's 7.9/10 (Strong Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer